NASDAQ:KZIA - Kazia Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 79.32 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.48
▲ +0.12 (1.28%)
1 month | 3 months | 12 months
Get New Kazia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KZIA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KZIA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.00
▲ +79.32% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Kazia Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 79.32% upside from the last price of $9.48.
Buy
The current consensus among 1 investment analysts is to buy stock in Kazia Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2021HC WainwrightInitiated CoverageBuy$17.00N/A
i
Rating by S. Lee at HC Wainwright
(Data available from 3/6/2016 forward)
Kazia Therapeutics logo
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Read More

Today's Range

Now: $9.48
$8.51
$9.74

50 Day Range

MA: $10.32
$9.36
$11.94

52 Week Range

Now: $9.48
$2.47
$15.85

Volume

146,708 shs

Average Volume

174,703 shs

Market Capitalization

$89.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Kazia Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Kazia Therapeutics in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for KZIA.

What is the current price target for Kazia Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Kazia Therapeutics in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 79.3%. HC Wainwright has the highest price target set, predicting KZIA will reach $17.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for Kazia Therapeutics in the next year.
View the latest price targets for KZIA.

What is the current consensus analyst rating for Kazia Therapeutics?

Kazia Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KZIA will outperform the market and that investors should add to their positions of Kazia Therapeutics.
View the latest ratings for KZIA.

What other companies compete with Kazia Therapeutics?

How do I contact Kazia Therapeutics' investor relations team?

Kazia Therapeutics' physical mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company's listed phone number is 61-2-9472-4101 and its investor relations email address is [email protected] The official website for Kazia Therapeutics is www.kaziatherapeutics.com.